News › Clinical Practice, Industry News

Maker of Botox Rival Soars as Treatment May Win Approval By February

September 20, 2018

The first new aesthetic neurotoxin to rival Allergan Plc’s Botox in almost a decade may be approved in time for Valentine’s Day.
Evolus Inc. Chief Executive Officer David Moatazedi says his company remains on track for a spring 2019 launch for its experimental wrinkle treatment, DWP-450. The Food and Drug Administration is now expected to make a decision on the drug by February 2 after the company failed to secure approval in May when the agency had questions on the company’s chemistry, manufacturing and controls processes.
Read more at Bloomberg >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • FDA Approves First New Sunscreen Ingredient in 20 Years
    • Allergan Aesthetics Releases ‘The Aesthetics Evolution: What Consumers Really Want’ Highlighting Consumer Motivations and Expectations in Aesthetics
    • Moxie Announces Treatment Plans
    • Pacific Reliance Medical M&A Advisors Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • Misinformation on Hyaluronic Acid (HA) Fillers Taking Over Your Practice? A New Fact-Based Campaign by Allergan Aesthetics Sets the Story Straight